One of Europe’s largest pharmaceutical plants is set to open in Transcarpathia this fall: what we know so far
10 April 06:52
The first phase of one of Europe’s largest pharmaceutical plants is set to launch this fall in Zakarpattia. This is a new facility by the Ukrainian company Biopharma, which will specialize in the production of pharmaceutical and immunobiological preparations from donated blood plasma. Prime Minister Yulia Svyrydenko announced this after visiting the production site, according to "Komersant Ukrainian"
According to Svyrydenko, the launch of the first phase is scheduled for September 2026. The new plant is intended to ensure a full cycle of blood plasma processing directly in Ukraine, which is strategically important for the development of the domestic pharmaceutical industry and the country’s medical security.
What is known about Biopharma’s new pharmaceutical plant
Biopharma’s future plant in Zakarpattia will become one of the largest pharmaceutical facilities in Europe. The company plans to produce drugs from human blood plasma, and the project itself is intended to provide Ukraine with a full cycle of processing this raw material within the country.
As of now, the main building and the raw materials warehouse have been constructed at the construction site, and the equipment has been installed. According to government officials and the company, the facility is in the final stages of preparation for the launch of the first phase.
How much has been invested in the project
Biopharma has already invested €67 million in the project, while the total cost of the plant’s first phase is estimated at €75 million. This makes the construction one of the largest private pharmaceutical investment projects in Ukraine during a full-scale war.
The company previously announced that it plans a large-scale expansion of production and investments of hundreds of millions of dollars in the medium term. The new plant in Zakarpattia is a key part of this strategy.
How many jobs will be created
The new facility is expected to create 150 jobs. For Zakarpattia, this means not only the emergence of a major industrial facility but also additional jobs in the region and the development of related infrastructure.
Why is this plant important for Ukraine
The main significance of the new facility lies in the fact that Ukraine will gain its own full-cycle blood plasma processing capability. This will reduce dependence on external supply chains, strengthen domestic supply of essential medications, and boost export potential.
Biopharma already supplies its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America. Therefore, the new plant in Zakarpattia is viewed not only as a production facility for the domestic market but also as part of a broader export strategy.
What is known about Biopharma
Biopharma Plasma LLC is a Ukrainian pharmaceutical company specializing in the development and production of high-tech drugs derived from donated human blood plasma. According to YouControl, the ultimate beneficial owners of the company are Kostyantyn Yefimenko and Vasyl Khmelnytskyi, who have indirect controlling influence.
What was the status of construction previously
Back in the fall of 2025, the company reported that work on the site was approximately 80% complete. At that time, the industrial facilities were essentially ready, and the energy infrastructure was connected. Compared to that stage, the project is now in the home stretch before launch.
What other plans does the company have
In addition to manufacturing, Biopharma is investing in biology education and support for talented children. According to Yulia Svyrydenko, the company has already organized two biology classes in Kyiv and two Bio-Schools in Kyiv and Bila Tserkva. Plans include the construction of another 25–30 Bio-Schools, the nearest of which are set to open in Uzhhorod, Lviv, and Dnipro.
